GET DAILY SIGNALSPrecision Optics Corporation (POCI): A Niche Optics Player in Medical and Defense Markets
Key Takeaways
- Precision Optics Corporation, Inc. (POCI) is a U.S.-based, micro-cap designer and manufacturer of specialized optical and illumination systems.
- The company serves two core end markets: medical imaging and minimally invasive surgery, and defense and aerospace components.
- Founded in 1982 and headquartered in Gardner, Massachusetts, it trades on the Nasdaq under the ticker POCI.
- Its product portfolio includes endoscopes, microprecision lenses, micro medical cameras, and 3D endoscopes used in surgical and robotic procedures.
- Revenue has grown rapidly in recent periods, although the company has historically operated at a net loss, reflecting its small scale and investment-heavy business model.
Company Overview
Precision Optics Corporation, Inc. designs, develops, manufactures, and sells high-precision optical and illumination systems and components. I follow the stock because it sits at the intersection of two long-term secular trends: the shift toward minimally invasive and robotic surgery, and the demand for advanced imaging and sensing in defense and aerospace applications.
As a micro-capitalization company, POCI is far smaller than large medical-device or optics conglomerates. This overview explains how the business operates, where its revenue comes from, and the factors that shape its market position. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Profile
Company History and Headquarters
Precision Optics Corporation was founded in December 1982 by Richard E. Forkey and is headquartered in Gardner, Massachusetts. The company has spent more than four decades developing expertise in high-precision optical components, particularly for medical and industrial applications. Its shares trade on the Nasdaq exchange.
Core Products and Business Model
Precision Optics operates primarily as a design and manufacturing partner, producing custom optical and illumination systems for original equipment manufacturers (OEMs) and other customers. Its medical instrumentation products include endoscopes and endocouplers, microprecision lenses, micro medical cameras, and 3D endoscopes used in minimally invasive surgical procedures performed by hospitals and physicians.
Beyond medical imaging, the company supplies components and assemblies to defense contractors and aerospace customers. This diversification across two distinct end markets is a defining feature of its business model, helping to balance demand cycles in any single sector.
Revenue Sources and Segments
The company's primary revenue sources are the design and production of medical optics and illumination systems and the manufacture of optical components for defense and aerospace programs. Rather than relying on high-volume consumer products, Precision Optics focuses on custom, specialized, and often lower-volume production runs, which can carry higher margins but also demand significant engineering resources.
Competitive Positioning and Markets Served
Within the broader optics industry, Precision Optics competes with substantially larger firms such as Coherent Corp. and Viavi Solutions, as well as established medical-device suppliers. Its market position rests on specialized engineering capabilities in micro-optics and endoscopic imaging rather than scale. The company serves hospitals and physicians indirectly through medical-device customers and works directly with defense and aerospace contractors in the United States.
Its financial profile reflects a small but growing operation. While revenue has expanded significantly in recent reporting periods, the company has generally reported net losses as it invests in capacity, engineering, and customer programs—a common characteristic of micro-cap technology manufacturers.
Why Investors Follow POCI
Investor interest in POCI centers on its exposure to growth-oriented niches. Minimally invasive and robotic surgery require ever-smaller, higher-resolution optical components, a demand driver that plays directly to the company's micro-optics expertise. Similarly, defense and aerospace programs increasingly rely on precision imaging and sensing, creating recurring design and manufacturing opportunities.
The company's role as a component and subsystem supplier means it can potentially benefit from growth in medical-device and defense spending without bearing the full cost and risk of marketing finished consumer products. Its long operating history and established customer relationships in specialized optics also represent competitive advantages that are difficult to replicate quickly. From what I see, this dual exposure adds a layer of resilience worth monitoring.
Risks and Important Considerations
Several factors merit careful attention. As a micro-cap company, Precision Optics has limited financial scale, and its historical net losses and reliance on external capital are notable risks. Customer concentration is another consideration: a significant share of revenue can come from a relatively small number of OEM and defense customers, so the loss of a key program could materially affect results.
The company also faces intense competition from larger, better-capitalized optics and medical-device manufacturers. Its defense and aerospace business is subject to government procurement cycles and regulation, while its medical business is tied to the pace of surgical-procedure volumes and device approvals. Finally, because it operates in technology-driven markets, continued innovation and engineering investment are essential to maintaining its market position. I’m watching this closely as part of my ongoing research.
Conclusion
Precision Optics Corporation occupies a specialized niche at the convergence of medical imaging and precision optics, supplying components that support minimally invasive and robotic surgery as well as defense and aerospace programs. Its combination of decades of engineering experience, a dual-market revenue base, and exposure to structural growth trends makes it a distinctive small-cap name within the optical technology space. At the same time, its modest scale, competitive pressures, and history of operating losses mean that understanding its business model and risks is essential before evaluating it as an investment.
Using Tickeron’s AI Tools for Research
In my own analysis, I often turn to Tickeron’s AI Screener to quickly compare companies like POCI against peers using technical indicators, fundamentals, and industry filters. It helps surface ideas that align with specific strategies without sifting through thousands of results manually. This tool has become a regular part of how I evaluate micro-cap opportunities in specialized sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
POCI's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for POCI turned positive on October 29, 2026. Looking at past instances where POCI's MACD turned positive, the stock continued to rise in 42 of 55 cases over the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on POCI as a result. In 91 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
POCI moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for POCI crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 19 of 27 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +5.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where POCI advanced for three days, in 111 of 163 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 104 of 152 cases where POCI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The 10-day RSI Indicator for POCI moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 18 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where POCI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
POCI broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.614) is normal, around the industry mean (4.955). P/E Ratio (-11.302) is within average values for comparable stocks, (40.806). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.113) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. POCI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POCI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement